EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New dosing strategy aims to fight lung cancer in the brain
Disease control Recruiting nowThis study is testing if giving a higher dose of the lung cancer drug furmonertinib every other day is better at controlling cancer that has spread to the lining of the brain and spinal cord. It will enroll 42 adults with advanced lung cancer that has this specific spread and has…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Apr 04, 2026 02:51 UTC
-
New approach targets lung Cancer's genetic engine
Disease control Recruiting nowThis early-stage trial is testing a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The drug is designed to find and break down the faulty protein that drives this type of cancer. Researchers …
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC